Literature DB >> 30352952

Emicizumab should be prescribed independent of immune tolerance induction.

Sandra Le Quellec1,2, Claude Negrier1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30352952      PMCID： PMC6199655          DOI： 10.1182/bloodadvances.2018015859

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


× No keyword cloud information.
  40 in total

1.  Fatal thrombosis after administration of activated prothrombin complex concentrates in a patient supported by extracorporeal membrane oxygenation who had received activated recombinant factor VII.

Authors:  Jack D Bui; George D Despotis; Elbert P Trulock; G Alexander Patterson; Lawrence T Goodnough
Journal:  J Thorac Cardiovasc Surg       Date:  2002-10       Impact factor: 5.209

2.  Prophylaxis usage, bleeding rates, and joint outcomes of hemophilia, 1999 to 2010: a surveillance project.

Authors:  Marilyn J Manco-Johnson; J Michael Soucie; Joan Cox Gill
Journal:  Blood       Date:  2017-02-09       Impact factor: 22.113

3.  Pharmacokinetics and pharmacodynamics of recombinant factor VIIa.

Authors:  C M Lindley; W T Sawyer; B G Macik; J Lusher; J F Harrison; K Baird-Cox; K Birch; S Glazer; H R Roberts
Journal:  Clin Pharmacol Ther       Date:  1994-06       Impact factor: 6.875

4.  A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects.

Authors:  Naoki Uchida; Takehiko Sambe; Koichiro Yoneyama; Naoki Fukazawa; Takehiko Kawanishi; Shinichi Kobayashi; Midori Shima
Journal:  Blood       Date:  2015-12-01       Impact factor: 22.113

5.  Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors.

Authors:  Cindy Leissinger; Alessandro Gringeri; Bülent Antmen; Erik Berntorp; Chiara Biasoli; Shannon Carpenter; Paolo Cortesi; Hyejin Jo; Kaan Kavakli; Riitta Lassila; Massimo Morfini; Claude Négrier; Angiola Rocino; Wolfgang Schramm; Margit Serban; Marusia Valentina Uscatescu; Jerzy Windyga; Bülent Zülfikar; Lorenzo Mantovani
Journal:  N Engl J Med       Date:  2011-11-03       Impact factor: 91.245

Review 6.  Prevention of bleeds in hemophilia patients with inhibitors: emerging data and clinical direction.

Authors:  Cindy A Leissinger
Journal:  Am J Hematol       Date:  2004-10       Impact factor: 10.047

7.  International workshop on immune tolerance induction: consensus recommendations.

Authors:  D M DiMichele; W K Hoots; S W Pipe; G E Rivard; E Santagostino
Journal:  Haemophilia       Date:  2007-07       Impact factor: 4.287

8.  Articular status of haemophilia patients with inhibitors.

Authors:  M Morfini
Journal:  Haemophilia       Date:  2008-11       Impact factor: 4.287

Review 9.  Inhibitor development in haemophilia B: an orphan disease in need of attention.

Authors:  Donna DiMichele
Journal:  Br J Haematol       Date:  2007-08       Impact factor: 6.998

10.  A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A.

Authors:  Flora Peyvandi; Pier M Mannucci; Isabella Garagiola; Amal El-Beshlawy; Mohsen Elalfy; Vijay Ramanan; Peyman Eshghi; Suresh Hanagavadi; Ramabadran Varadarajan; Mehran Karimi; Mamta V Manglani; Cecil Ross; Guy Young; Tulika Seth; Shashikant Apte; Dinesh M Nayak; Elena Santagostino; Maria Elisa Mancuso; Adriana C Sandoval Gonzalez; Johnny N Mahlangu; Santiago Bonanad Boix; Monica Cerqueira; Nadia P Ewing; Christoph Male; Tarek Owaidah; Veronica Soto Arellano; Nathan L Kobrinsky; Suvankar Majumdar; Rosario Perez Garrido; Anupam Sachdeva; Mindy Simpson; Mathew Thomas; Ezio Zanon; Bulent Antmen; Kaan Kavakli; Marilyn J Manco-Johnson; Monica Martinez; Esperanza Marzouka; Maria G Mazzucconi; Daniela Neme; Angeles Palomo Bravo; Rogelio Paredes Aguilera; Alessandra Prezotti; Klaus Schmitt; Brian M Wicklund; Bulent Zulfikar; Frits R Rosendaal
Journal:  N Engl J Med       Date:  2016-05-26       Impact factor: 91.245
View more
  6 in total

1.  Origins and organization of the NHLBI State of the Science Workshop: Generating a national blueprint for future research on factor VIII inhibitors.

Authors:  Denise E Sabatino; Steven W Pipe; Diane J Nugent; J Michael Soucie; W Craig Hooper; W Keith Hoots; Donna M DiMichele
Journal:  Haemophilia       Date:  2019-07       Impact factor: 4.287

Review 2.  Translational Potential of Immune Tolerance Induction by AAV Liver-Directed Factor VIII Gene Therapy for Hemophilia A.

Authors:  Benjamin J Samelson-Jones; Valder R Arruda
Journal:  Front Immunol       Date:  2020-04-28       Impact factor: 7.561

3.  Emicizumab in children: bleeding episodes and outcome before and after transition to Emicizumab.

Authors:  Hannah Glonnegger; Felicia Andresen; Friedrich Kapp; Stefano Malvestiti; Martin Büchsel; Barbara Zieger
Journal:  BMC Pediatr       Date:  2022-08-15       Impact factor: 2.567

Review 4.  Bispecific Antibodies and Advances in Non-Gene Therapy Options in Hemophilia.

Authors:  Midori Shima
Journal:  Res Pract Thromb Haemost       Date:  2020-04-28

Review 5.  Protein-Engineered Coagulation Factors for Hemophilia Gene Therapy.

Authors:  Benjamin J Samelson-Jones; Valder R Arruda
Journal:  Mol Ther Methods Clin Dev       Date:  2018-12-31       Impact factor: 6.698

Review 6.  Clinical Evidence and Safety Profile of Emicizumab for the Management of Children with Hemophilia A.

Authors:  Sandra Le Quellec
Journal:  Drug Des Devel Ther       Date:  2020-02-03       Impact factor: 4.162
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.